Editorial illustration for Isomorphic Labs Raises USD 5B to Advance AI Drug Candidates Toward Clinical Trials
Isomorphic Labs Raises $5B for AI Drug Development
Isomorphic Labs closed a $5 billion Series C on November 12, just six months after its $2.1 billion Series B in May, putting the company's total haul for the year above $7 billion. Greenoaks and Sequoia Capital co-led the round, with Andreessen Horowitz joining as a new backer. Every existing investor came back for more, including Alphabet's GV and Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund.
The London-based company spun out of Google DeepMind in 2021 and builds its drug-design work on AlphaFold, the protein-structure model that won DeepMind researchers a Nobel Prize in chemistry. Isomorphic runs a stack of simulation models meant to map out chemical space and speed up how new drugs get designed, and it already has partnerships with Eli Lilly, Novartis, and Johnson & Johnson. The company says its internal pipeline has produced positive preclinical results in oncology and immunology, and the new money is meant to push those candidates toward clinical trials while expanding into other types of medicine.
The raise also marks the first since CEO Demis Hassabis stepped back from running DeepMind day-to-day.
Isomorphic Labs builds an AI drug-design engine that uses a slew of simulation AI models that explore various areas of chemistry to help the company design drugs. The company, whose work builds on DeepMind’s breakthrough AlphaFold protein-folding AI model, said its program has yielded “positive preclinical results” in oncology and immunology.
Why this matters
A $5 billion round is a bet on AlphaFold's commercial afterlife, not just another AI funding story. Isomorphic Labs still hasn't put a drug into a human trial, and the gap between "positive preclinical" results and an approved therapy is where most biotech money disappears. For founders pitching AI-for-science, this round resets expectations: investors like Sequoia and Greenoaks are willing to write huge checks years before revenue, as long as the underlying model (here, DeepMind's protein-folding work) has a track record.
That's a narrow bar most startups can't clear. For researchers, the real test comes when Isomorphic has to defend its "AI drug-design engine" against the FDA's clinical pipeline, not against benchmarks. Watch whether Andreessen Horowitz's entry signals a broader shift of AI capital from chatbots into wet-lab science, and whether Alphabet's continued backing through GV and Capital G means Google sees this as a genuine business, not a research showcase.
The next milestone to track is simple: which candidate actually reaches a trial, and when.
Common Questions Answered
How much funding did Isomorphic Labs raise in 2024 and who led the Series C round?
Isomorphic Labs closed a $5 billion Series C on November 12, bringing its total funding for the year above $7 billion when combined with its $2.1 billion Series B from May. Greenoaks and Sequoia Capital co-led the Series C round, with Andreessen Horowitz joining as a new investor alongside returning backers including Alphabet's GV and Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund.
What is Isomorphic Labs' AI drug-design engine based on and what therapeutic areas has it shown results in?
Isomorphic Labs' AI drug-design engine builds on DeepMind's breakthrough AlphaFold protein-folding AI model and uses multiple simulation AI models to explore various areas of chemistry for drug design. The company has reported positive preclinical results in oncology and immunology, though it has not yet advanced any drug candidates into human clinical trials.
When did Isomorphic Labs spin out from Google DeepMind and what is the significance of this funding round?
Isomorphic Labs spun out of Google DeepMind in 2021 as a London-based company focused on commercializing AI-driven drug discovery. The $5 billion Series C represents a major bet on AlphaFold's commercial potential and signals that investors like Sequoia and Greenoaks are willing to commit substantial capital years before revenue generation, as long as the underlying AI model shows promise.
Why does the gap between preclinical results and approved therapy matter for evaluating Isomorphic Labs' funding?
The gap between positive preclinical results and an approved therapy is historically where most biotech funding disappears, making it a critical risk factor in drug development. Although Isomorphic Labs has achieved positive preclinical results in oncology and immunology, the company has not yet entered human clinical trials, meaning significant development and regulatory hurdles remain before commercialization.
Further Reading
- Papers with Code - Latest NLP Research - Papers with Code
- Hugging Face Daily Papers - Hugging Face
- ArXiv CS.CL (Computation and Language) - ArXiv